RBC Capital rated the company’s stock at “outperform.” Boston Scientific stock has a 52-week high of $18.40 and a 52-week low of $11.10, according to the report.
More articles on gastroenterology:
7 things for gastroenterologists to know for today – April 17, 2015
Alternative payment models in GI: What’s on the horizon?
3 GI physicians making headlines – April 17, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.